Approximately 20% of women with advanced-stage ovarian cancer survive beyond 12 years
after treatment and are effectively cured. Initial therapy for ovarian cancer comprises surgery …

Ovarian cancer represents one of the most aggressive female tumors worldwide. Over the
decades, the therapeutic options for the treatment of ovarian cancer have been improved …

Background The understanding of ovarian cancer pathogenesis has recently shifted to
recognize distinct changes in how ovarian cancer histotypes are defined. Using the 2014 …

In a recent report,[Zhang et al.(2003) N. Engl. J. Med. 348, 203–213], the presence of CD3+
tumor-infiltrating lymphocytes (TILs) was found to correlate with improved survival in …

Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …

Background Ovarian cancer has a high case–fatality ratio, with most women not diagnosed
until the disease is in its advanced stages. The United Kingdom Collaborative Trial of …

Purpose: Endometriosis, a largely benign, chronic inflammatory disease, is an independent
risk factor for endometrioid and clear cell epithelial ovarian tumors. We aimed to identify …

MicroRNAs are small non-coding RNAs which play important roles in tumor progression.
MiR-383-5p has been characterized as a cancer suppressor in several cancers. The aim of …

OBJECTIVE: We investigate what role stage at diagnosis bears in international differences
in ovarian cancer survival. METHODS: Data from population-based cancer registries in …

OBJECTIVE: The progression-free and median survival of patients with advanced ovarian
cancer has not appreciably improved over the last decade. Novel targeted therapies …